{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:36:53Z","timestamp":1777581413369,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","surgpath.theclinics.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.path.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T09:31:50Z","timestamp":1498555910000},"page":"675-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hematopoietic Tumors Primarily Presenting in Bone"],"prefix":"10.1016","volume":"10","author":[{"given":"Arjen H.G.","family":"Cleven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pancras C.W.","family":"Hogendoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2017.04.011_bib1","first-page":"202","article-title":"WHO classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"20","key":"10.1016\/j.path.2017.04.011_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.path.2017.04.011_bib3","series-title":"WHO classification of tumours of soft tissue and bone","first-page":"312","author":"Fletcher","year":"2013"},{"issue":"11","key":"10.1016\/j.path.2017.04.011_bib4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.path.2017.04.011_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2017.04.011_bib6","series-title":"Orthopaedic pathology","author":"Vigorita","year":"2016"},{"issue":"10","key":"10.1016\/j.path.2017.04.011_bib7","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.path.2017.04.011_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semdp.2014.01.004","article-title":"Primary lymphoma of bone: a review","volume":"31","author":"Bhagavathi","year":"2014","journal-title":"Semin Diagn Pathol"},{"issue":"12","key":"10.1016\/j.path.2017.04.011_bib9","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/sj.leu.2401582","article-title":"Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases","volume":"13","author":"Heyning","year":"1999","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.path.2017.04.011_bib10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/jcp.2010.078915","article-title":"Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone","volume":"63","author":"Heyning","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"issue":"3","key":"10.1016\/j.path.2017.04.011_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00428-013-1372-x","article-title":"Nuclear factor-kappaB activation in primary lymphoma of bone","volume":"462","author":"Koens","year":"2013","journal-title":"Virchows Arch"},{"issue":"9","key":"10.1016\/j.path.2017.04.011_bib12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/jcp.2008.063156","article-title":"Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype","volume":"62","author":"Heyning","year":"2009","journal-title":"J\u00a0Clin Pathol"},{"issue":"10","key":"10.1016\/j.path.2017.04.011_bib13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00256-007-0335-1","article-title":"MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance","volume":"36","author":"Heyning","year":"2007","journal-title":"Skeletal Radiol"},{"issue":"13","key":"10.1016\/j.path.2017.04.011_bib14","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2013-01-475772","article-title":"Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma","volume":"122","author":"Bonetti","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.path.2017.04.011_bib15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/gcc.22172","article-title":"Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities","volume":"53","author":"Specht","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.path.2017.04.011_bib16","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/PAS.0000000000000223","article-title":"BCOR-CCNB3 (Ewing-like) sarcoma: a clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma","volume":"38","author":"Puls","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.path.2017.04.011_bib17","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1158\/1078-0432.CCR-08-2184","article-title":"The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology","volume":"15","author":"Szuhai","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2017.04.011_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cancergencyto.2006.07.007","article-title":"Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma","volume":"172","author":"Szuhai","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.path.2017.04.011_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cyt.12079","article-title":"CD99-positive undifferentiated round cell sarcoma diagnosed on fine needle aspiration cytology, later found to harbour a CIC-DUX4 translocation: a recently described entity","volume":"25","author":"Kajtar","year":"2014","journal-title":"Cytopathology"},{"issue":"25","key":"10.1016\/j.path.2017.04.011_bib20","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2017.04.011_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of high-grade B cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements","volume":"129","author":"Sesques","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.path.2017.04.011_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1016\/j.path.2017.04.011_bib23","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2017.04.011_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jmoldx.2011.07.007","article-title":"Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality","volume":"14","author":"Zamo","year":"2012","journal-title":"J\u00a0Mol Diagn"},{"issue":"2","key":"10.1016\/j.path.2017.04.011_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.leu.2404482","article-title":"Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"21","author":"Langerak","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.path.2017.04.011_bib26","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/PAS.0b013e3181b314ce","article-title":"Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature","volume":"33","author":"Bhagavathi","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.path.2017.04.011_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00428-013-1519-9","article-title":"The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone","volume":"464","author":"Rajnai","year":"2014","journal-title":"Virchows Arch"},{"issue":"9881","key":"10.1016\/j.path.2017.04.011_bib28","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.path.2017.04.011_bib29","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2016-08-733790","article-title":"Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis","volume":"128","author":"Chakraborty","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.path.2017.04.011_bib30","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.path.2017.04.011_bib31","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjh.14140","article-title":"Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age","volume":"174","author":"Rigaud","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.path.2017.04.011_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.0105-2896.2009.00883.x","article-title":"Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage","volume":"234","author":"Egeler","year":"2010","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.path.2017.04.011_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/path.2167","article-title":"Differences in telomerase expression by the CD1a+ cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease","volume":"212","author":"da Costa","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.path.2017.04.011_bib34","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.14694\/EdBook_AM.2014.34.e441","article-title":"Biological and therapeutic implications of the BRAF pathway in histiocytic disorders","author":"Arceci","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.path.2017.04.011_bib35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","article-title":"MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis","volume":"54","author":"Nelson","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"20","key":"10.1016\/j.path.2017.04.011_bib36","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2013-06-511139","article-title":"Somatic activating ARAF mutations in Langerhans cell histiocytosis","volume":"123","author":"Nelson","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.path.2017.04.011_bib37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1084\/jem.20030137","article-title":"Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis","volume":"197","author":"Annels","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.path.2017.04.011_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1471-4906(03)00063-2","article-title":"Langerhans-cell histiocytosis 'insight into DC biology'","volume":"24","author":"Laman","year":"2003","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1016\/j.path.2017.04.011_bib39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.20041785","article-title":"Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis","volume":"201","author":"da Costa","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"9","key":"10.1016\/j.path.2017.04.011_bib40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1586\/1744666X.2015.1060857","article-title":"The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm","volume":"11","author":"Haroche","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.path.2017.04.011_bib41","first-page":"389","article-title":"Langerhans cell histiocytosis and Erdheim-Chester disease, a continuity?","volume":"10","author":"Parreau","year":"2016","journal-title":"Rev Med Interne"},{"issue":"25","key":"10.1016\/j.path.2017.04.011_bib42","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"Heritier","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.path.2017.04.011_bib43","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1182\/blood-2015-01-625491","article-title":"Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis","volume":"125","author":"Heritier","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.path.2017.04.011_bib44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00043426-200212000-00009","article-title":"Expression of cell cycle-related gene products in Langerhans cell histiocytosis","volume":"24","author":"Schouten","year":"2002","journal-title":"J\u00a0Pediatr Hematol Oncol"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918117300715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918117300715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T10:23:53Z","timestamp":1535711033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918117300715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1875918117300715"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2017.04.011","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Tumors Primarily Presenting in Bone","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}